ArticleScientific reports2025
Eco-friendly spectrofluorimetric determination of remdesivir in the presence of its metabolite in human plasma for therapeutic monitoring in COVID-19 patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sustainable synchronized spectrofluorimetric determination of remdesivir and baricitinib: a first-derivative synchronous approach with multi-color and GLANCE assessment.Scientific reports · 2026Article
- A sensitive, aqueous-based spectrofluorimetric approach for the determination of favipiravir in presence of its acid-induced degradation product.BMC chemistry · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global outbreak of the novel coronavirus (COVID-19) has highlighted the urgent need for innovative therapeutic solutions. Remdesivir (REM) was the first drug granted approval by the US FDA for treating hospitalized COVID-19 patients. A selective and sensitive derivative spectrofluorimetric method has been developed and validated for the determination of Remdesivir (REM) in presence of its Alkaline-induced degradation product (AKDP), which is also known to be its metabolite (GS-441524). The method utilized the intrinsic fluorescence properties of REM, achieving a linear response within the range of 3.0-120.0 ng/mL at 428.3 nm using first-order derivative. Methodological parameters were optimized to ensure high sensitivity, with detection and quantification limits of 1.12 and 3.67 ng/mL, respectively. This approach successfully quantified REM in pure form, intravenous infusions, and spiked human plasma. Recovery rates in plasma were satisfactory at 97.64 ± 1.87, confirming the method's suitability for therapeutic drug monitoring (TDM) in COVID-19 patients. Additionally, the environmental sustainability of the method was evaluated using GAPI, AGREE, and RGB12 metrics, underscoring its green and eco-friendly characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.